Outcome of hepatoblastoma: experience with 63 patients received chemotherapy with the regimen C5V

Gongbao Liu,Baihui Liu,Kai Li,Kuiran Dong,Xianmin Xiao

DOI: https://doi.org/10.3760/cma.j.issn.0578-1310.2015.02.011

2015-01-01

Abstract:Objective To summarize the experience of the chemotherapy regimen cisplatin + fluorouracil + vincristine (C5V) for hepatoblastoma,and analyze the factors associated the outcome.Method A retrospective analysis was conducted for the outcome of hepatoblastoma.Sixty-three patients who received the regimen of C5V as the first choice of chemotherapy were reviewed,including 37 males and 26 females.The age at diagnosis ranged from 2 days after birth to 124 months,median 15 months.Four patients with stage Ⅰ,16 patients with stage Ⅱ,28 patients with stage Ⅲ,15 patients with stage Ⅳ disease were enrolled in the study.Nine patients had primary tumor resection while the remain by 54 received neoadjuvant chemotherapy.The median follow-up time was 30 months.Result Forty patients had delayed surgery,including 35 patients with regimen C5V alone,the others were treated with regimen C5V and cisplatin + adriamycin (CITA).The mean time of neojuvant chemotherapy was (3.4-1.7) cycles.The mean time of chemotherapy after surgery was (5.3 ±2.0) cycles.In 12 cases the (24.5％) tumor recurred after surgery.The margin of resection less than 0.5 cm,vascular invasion,stage Ⅲ or Ⅳ disease were all the high risks of relapse (P =0.049,0.001,0.022,respectively).Two-year overall survival (OS) and 5-year OS of the study was 61.1％ and 58.7％,respectively.The 2-year OS and 5-year OS of stage Ⅰ to Ⅲ were 75.0％ and 75.0％,100.0％ and 100.0％,65.8％ and 61.4％.The 1-year OS and 3-year OS of stage Ⅳ was 20.0％,13.3％,respectively.Univariate analysis showed that age at diagnosis less than 60 months,vascular invasion,thrombocythemia at diagnosis,stage Ⅲ or Ⅳ,tumor resection was the prognostic factor (P =0.019,＜ 0.001,0.011,＜ 0.001,respectively).Multivariate analysis showed that tumor resection and age at diagnosis less than 60 months were both the prognostic factor (P ＜ 0.001,0.004,respectively).Conclusion The regimen of C5V is useful for hepatoblastoma.Tumor resection is the key factor of treatment.Prognostic factor is composed of age,stage,and clinical sign at diagnosis.